In modern endocrinology and molecular peptide research, single-target secretagogues often reach pharmacological plateaus. To overcome these limits, investigators frequently study dual-agonist combinations. Among the most widely documented pairs is the CJC-1295 (No DAC) and Ipamorelin peptide blend.

By co-targeting two distinct receptor pathways on anterior pituitary somatotrophs, this blend allows researchers to examine synergistic growth hormone (GH) secretion dynamics.Unlike synthetic compounds that cause erratic hormone spikes, CJC-1295 (No DAC) combined with Ipamorelin mirrors physiological pulsatility.

This comprehensive research guide reviews the molecular structure, receptor pathways, pharmacokinetic profile, and pre-clinical applications of the CJC-1295 (No DAC) / Ipamorelin Blend

supplied by Vitale Peptide.

What Is CJC-1295 (No DAC) / Ipamorelin?

The CJC-1295 (No DAC) / Ipamorelin combination is a specialized laboratory research blend composed of two synthetic growth hormone secretagogues:

1. CJC-1295 (No DAC)— Also known as Modified GRF 1-29 (Mod GRF 1-29).
2. Ipamorelin — A highly selective pentapeptide ghrelin receptor agonist.

               +-------------------------------------------------------+
               |        ANTERIOR PITUITARY SOMATOTROPH CELL            |
               +-------------------------------------------------------+
                                   |
         +-------------------------+-------------------------+
         |                                                   |
         v                                                   v
+-------------------------+                         +-------------------------+
|     GHRH RECEPTOR       |                         |    GHSR-1a RECEPTOR     |
|   CJC-1295 (No DAC)     |                         |       Ipamorelin        |
+-------------------------+                         +-------------------------+
         |                                                   |
         v                                                   v
[ Adenylate Cyclase / cAMP ]                         [ Phospholipase C / Ca²⁺ ]
         |                                                   |
         |         +-------------------------------+         |
         +-------->| SYNERGISTIC PULSATILE RELEASE |<--------+
                   |  Growth Hormone (GH) Secretion|
                   +-------------------------------+

While both agents stimulate endogenous GH synthesis, they do so through complementary intracellular pathways. Research indicates that combining a GHRH analogue with a ghrelin mimetic produces a greater GH pulse amplitude than either compound administered alone.

Researchers interested in exploring dual-pathway secretagogues can view the high-purity CJC-1295 No DAC / Ipamorelin research vial

directly on Vitale Peptide.

Deconstructing the Components: Biochemical Profiles

To understand why this pairing is prominent in endocrine research, we must analyze each molecule individually.

1. CJC-1295 (No DAC) / Modified GRF 1-29

Native Growth Hormone-Releasing Hormone (GHRH) consists of 44 amino acids.However, the first 29 amino acids retain full biological activity.Natural GHRH(1-29) has a short half-life in laboratory models (under 7 minutes) due to rapid cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4).

Modified GRF 1-29 alters four amino acids at positions 2, 8, 15, and 27:

• Position 2 (D-Alanine):Protects the peptide against DPP-4 degradation.
• Positions 8, 15, and 27:Enhance chemical stability and receptor binding affinity.

These structural modifications extend the half-life to approximately 25–30 minutes without altering its interaction with the GHRH receptor.

2. Ipamorelin

Ipamorelin is a pentapeptide with the sequence Aib-His-D-2Nal-D-Phe-Lys-NH2. It is classified as a Growth Hormone Secretagogue (GHS) that selectively targets the ghrelin receptor (GHSR-1a).

Key properties of Ipamorelin include:

• High Receptor Selectivity:Unlike earlier secretagogues like GHRP-2 or GHRP-6, Ipamorelin does not significantly elevate cortisol, prolactin, or adrenocorticotropic hormone (ACTH).
• Systemic Half-Life:Features an approximate 2-hour half-life in animal models, making it ideal for acute pulse timing studies.

Receptor Synergy: How the Pathways Interact

The core mechanism of the CJC-1295 (No DAC) / Ipamorelin blend

lies in its dual intracellular signal transduction.

+-----------------------------------------------------------------------------------+
|                        MOLECULAR MECHANISM OF SYNERGY                             |
+-----------------------------------------------------------------------------------+
| 1. CJC-1295 (No DAC)  ---> Binds GHRH Receptor  ---> Increases intracellular cAMP |
|                                                      & primes GH vesicle pools    |
| 2. Ipamorelin         ---> Binds GHSR-1a        ---> Triggers Inositol Triphosphate|
|                            Receptor                  (IP3) & Ca²⁺ influx          |
+-----------------------------------------------------------------------------------+
| RESULT: Amplified exocytosis of loaded secretory vesicles yielding larger GH pulse|
+-----------------------------------------------------------------------------------+

1. GHRH Receptor Activation (CJC-1295 No DAC): Binding to GHRH receptors activates adenylate cyclase, raising cyclic adenosine monophosphate (cAMP). This stimulates gene transcription of growth hormone and loads GH-containing vesicles into the somatotroph’s secretory reserve.
2. Ghrelin Receptor Activation (Ipamorelin): Binding to GHSR-1a initiates the phospholipase C pathway, raising intracellular free calcium ($\text{Ca}^{2+}$). This triggers immediate exocytosis (release) of those pre-loaded vesicles.

When both receptors are engaged simultaneously, CJC-1295 No DAC expands the available reserve of GH vesicles while Ipamorelin promotes exocytosis.This dual action produces a higher GH pulse amplitude than single-receptor agonism.

Why “No DAC” Is Critical for Pulsatile GH Research

When reviewing CJC-1295 literature, researchers must distinguish between two primary chemical forms:

Property	CJC-1295 (No DAC) / Mod GRF 1-29	CJC-1295 (With DAC)
Chemical Additive	None (29-amino acid chain)	Maleimidopropionyl-lysine tail
Albumin Binding	Transient / minimal	Covalent binding to serum albumin
Half-Life	~25 to 30 minutes	~6 to 8 days
Secretion Profile	Pulsatile (discrete, acute pulses)	Continuous / Tonic elevation
Desensitization Risk	Low (preserves inter-pulse troughs)	Higher potential for GHRHR downregulation

In physiological conditions, growth hormone is naturally secreted in episodic bursts rather than continuous streams. Pulsatile GH secretion maintains peripheral target cell receptor sensitivity and normal feedback loops.

Because CJC-1295 (No DAC) has a half-life of 30 minutes, it clears rapidly, preserving natural baseline troughs between pulses.This makes the No DAC blend the preferred model for studies seeking to preserve natural somatotroph signaling rhythms.

Key Areas of Pre-Clinical Investigation

Pre-clinical literature across cell cultures and animal models highlights several primary research domains for this secretagogue combination.

                RESEARCH DOMAINS: CJC-1295 NO DAC / IPAMORELIN
                ==============================================

      +-------------------------+         +-------------------------+
      |  Adipose & Lipolysis    |         |  Musculoskeletal        |
      |  - HSL / ATGL activation|         |  - Lean tissue signaling|
      |  - Visceral fat models  |         |  - Osteoblast activity  |
      +-------------------------+         +-------------------------+
                   ^                                   ^
                   |                                   |
                   +-----------------+-----------------+
                                     |
                         +-----------------------+
                         | Cellular Recovery     |
                         | & Sleep Architecture  |
                         | - Slow-wave GH bursts |
                         | - Downstream IGF-1    |
                         +-----------------------+

1. Metabolic Function & Lipolytic Signaling

Growth hormone modulates lipid and carbohydrate metabolism.In rodent fat models, GH activation increases expression of hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL).

These lipolytic enzymes accelerate the mobilization of stored visceral triglycerides into circulating free fatty acids.Researchers utilize the CJC-1295 No DAC / Ipamorelin blend to study metabolic rate fluctuations and substrate utilization shifts during energy restriction.

2. Connective Tissue & Bone Density Research

Downstream GH signaling stimulates hepatic production of Insulin-like Growth Factor 1 (IGF-1). IGF-1 acts on osteoblasts and chondrocytes to promote extracellular matrix synthesis.

Pre-clinical studies indicate that dual-pathway GH stimulation supports osteoblast proliferation and collagen deposition, providing valuable data for bone density and connective tissue maintenance models.

3. Sleep Architecture and Deep Sleep Waves

Natural peak GH pulses occur during slow-wave (delta) sleep. Endocrine researchers study how timing secretagogue exposure relative to sleep-wake cycles affects slow-wave sleep duration, nocturnal repair markers, and metabolic recovery.

Comparative Research Profiles in Endocrine Literature

To put CJC-1295 (No DAC) / Ipamorelin into perspective, researchers often evaluate it alongside other standard secretagogues:

               SECRETAGOGUE RECEPTOR SELECTIVITY SPECTRUM
               ==========================================

  [ Low Selectivity ] --------------------------------> [ High Selectivity ]
  GHRP-6 / GHRP-2             Hexarelin               Ipamorelin + Mod GRF
  - Prolactin elevation       - Moderate cortisol     - Minimal prolactin
  - Cortisol elevation          elevation             - Minimal cortisol
  - Strong appetite spikes    - Desensitization       - Clean GH pulse

Studies published in endocrinology journals like the Journal of Clinical Endocrinology & Metabolism document that selective agonists allow clean physiological measurement without confounding stress-hormone variables.

Handling, Reconstitution, and Quality Standards

When sourcing peptide blends for analytical laboratory use, maintaining precise experimental protocols is essential.

+-----------------------------------------------------------------------------------+
|                        LABORATORY QUALITY CHECKLIST                               |
+-----------------------------------------------------------------------------------+
| [✓] Purity ≥ 98% validated via Reverse-Phase HPLC (RP-HPLC)                      |
| [✓] Mass Identity verified via ESI-MS or MALDI-TOF Mass Spectrometry               |
| [✓] Lyophilized format for thermal stability                                     |
| [✓] Reconstitution with Bacteriostatic Water under sterile laminar flow hood     |
| [✓] Storage at -20°C (lyophilized) or 2°C to 8°C (reconstituted solution)         |
+-----------------------------------------------------------------------------------+

1. Lyophilization: High-purity peptides are freeze-dried into a stable cake format to maintain molecular stability during storage and transport.
2. Reconstitution: In vitro protocols typically reconstitute lyophilized powders with Bacteriostatic Water or Sterile Normal Saline under a laminar flow hood to prevent microbial contamination.
3. Storage Temperature: Unreconstituted vials should be stored at $-20^\circ\text{C}$ for long-term stability. Once reconstituted, liquid solutions are kept between $2^\circ\text{C}$ and $8^\circ\text{C}$ and used within a defined experimental window.

At Vitale Peptide, all products undergo strict batch testing to confirm molecular identity and high purity for laboratory applications. Explore the complete collection of research-grade peptides on Vitale Peptide.

Conclusion

The CJC-1295 (No DAC) / Ipamorelin research blend represents a refined tool in combinatorial endocrinology.By leveraging both GHRH and ghrelin receptor pathways, it offers a dual-action approach for studying growth hormone dynamics, IGF-1 regulation, metabolic lipolysis, and cellular recovery.

For verified, laboratory-grade compounds with batch purity documentation, explore the CJC-1295 No DAC / Ipamorelin 10mg product page

at Vitale Peptide today.

Research Compliance Disclaimer

The compounds described herein, including CJC-1295 (No DAC) and Ipamorelin, are intended strictly for laboratory, analytical, and in-vitro research purposes only. They are not intended for human or animal consumption, medical diagnosis, treatment, or therapeutic use. All research must be conducted by qualified personnel adhering to proper laboratory safety guidelines.